ProQR Therapeutics (PRQR) news
Recent news
ProQR Therapeutics NV - files to register resale of up to 3.03 mln ordinary shares - SEC filing
ProQR Therapeutics N.V. (Nasdaq: PRQR) has filed with the U.S. Securities and Exchange Commission (SEC) to register the resale of up to 3.03 million of its ordinary shares. The filing, made under a registration statement, allows existing shareholders to sell their shares in the public market,…
AInvest Wire · Jul 6, 2026ProQR Therapeutics NV - to use proceeds for research, clinical development, and general corporate purposes
AInvest Wire · Jun 25, 2026ProQR Therapeutics NV - Eli Lilly to purchase 5.1 mln ProQR shares at $1.81/share for $9.2 mln
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that Eli Lilly and Company, an existing shareholder and strategic partner, agreed to purchase 3,523,538 ordinary shares in a concurrent private placement at a price per share of $3.50, resulting in total gross proceeds of approximately $12.3 million…
AInvest Wire · Jun 25, 2026ProQR prices $50.0 million underwritten registered direct offering and concurrent private placement
AInvest Wire · Jun 25, 2026ProQR Therapeutics NV - Phase 2 program expected to start mid-2027 with interim data by mid-2028
ProQR Therapeutics N.V. (Nasdaq: PRQR) has outlined key milestones for its pipeline, including the initiation of a Phase 2 program in mid-2027, with interim data expected by mid-2028. This timeline is part of the company’s broader strategy to advance its Axiomer™ RNA editing platform and expand its…
AInvest Wire · Jun 25, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.